Amarin Corporation Plc (DE:EH3)
NASDAQ:EH3
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.01Last Year’s EPS
-0.03Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed clear operational progress: revenue growth, meaningful expense reductions, improved operating losses, second consecutive quarter of positive operating cash flow, a strong cash position with no debt, and accelerating international traction via the Recordati partnership. Offsetting risks include materially higher COGS in the near term (62% YoY increase), quarter-to-quarter revenue variability from the partnered model, ongoing U.S. generic competition risk, and remaining restructuring charges. On balance, the positive developments (cash generation, cost savings, market-share gains, favorable guideline positioning, and international rollout momentum) outweigh the near-term headwinds.Company Guidance
Revenue Growth and Top-Line Metrics
Total net revenue rose to $45.1 million in Q1 2026 from $42.0 million in Q1 2025, an increase of approximately 7.4% year-over-year. U.S. revenue was broadly consistent with Q1 2025. The overall IPE market grew ~3% YoY in Q1 2026.
U.S. Market Share and Branded Prescription Growth
Amarin's share of the IPE market increased to 48% at March 31, 2026 from 42% a year earlier (+6 percentage points). VASCEPA branded prescriptions rose 17% in Q1 2026 versus Q1 2025, demonstrating continued branded demand despite generic competition.
European Partnership Traction (Recordati)
Under the Recordati partnership, Q1 2026 European product revenue was $4.9 million and more than doubled (+113%) versus Q4 2025 ($2.3 million), driven by $3.0 million of supply shipments to Recordati in Q1. Recordati has commenced sales of VAZKEPA in 10 countries; Europe IP protection extends through 2039 across 59 countries.
Global Commercial Expansion and Pipeline Filings
Continued rest-of-world growth with partners in China, Australia, Canada and the Middle East (Q1 2026 RoW revenue $2.8 million vs none in Q1 2025). Preparing for early-2027 launches in South Korea and Singapore; regulatory reviews in Thailand and the Philippines; Vietnam filing submitted in Q1 2026 and Malaysia planned for Q2 2026.
Operating Expense Reductions and Restructuring Progress
Total operating expenses declined 31% YoY ($12.8 million) to $29.1 million in Q1 2026. Excluding a $3.3 million restructuring charge, operating expenses were $25.8 million, a 38% YoY reduction. SG&A declined 42% YoY and represented 47% of net sales in Q1 2026 versus 87% in Q1 2025. Company expects ~$70 million in total operating expense savings by June 30, 2026.
Improved Profitability and Cash Generation
Operating loss narrowed to $11.3 million in Q1 2026 from $16.8 million in Q1 2025; excluding restructuring charges, operating loss was $8.0 million. Generated positive operating cash flow of $6.4 million in Q1 2026 (second consecutive quarter). Company ended the quarter with $308 million in cash and investments (up from $303 million at year-end 2025), no debt, and working capital of $450 million, and expects to be cash-flow positive for full-year 2026.
Favorable Clinical and Guideline Developments
Updated ACC/AHA 2026 lipid management guideline positions icosapent ethyl (VASCEPA) as the only primary triglyceride-lowering medication shown to reduce cardiovascular event risk on top of statin therapy. Company cites >500 peer-reviewed publications and >30 million prescriptions by >250,000 HCPs supporting the therapy's evidence base.
DE:EH3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:EH3 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | €11.80 | €11.70 | -0.85% |
Feb 25, 2026 | €13.20 | €11.80 | -10.61% |
Oct 29, 2025 | €16.00 | €14.30 | -10.62% |
Jul 30, 2025 | €12.60 | €12.90 | +2.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amarin Corporation Plc (DE:EH3) report earnings?
Amarin Corporation Plc (DE:EH3) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is Amarin Corporation Plc (DE:EH3) earnings time?
Amarin Corporation Plc (DE:EH3) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Amarin Corporation Plc stock?
The P/E ratio of Amarin is N/A.
What is DE:EH3 EPS forecast?
DE:EH3 EPS forecast for the fiscal quarter 2026 (Q2) is -0.01.